NCT01819870

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 20 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.

Detailed description

Healthy male subjects are administrated multiple-dose over the period I and II (Crossover) of dilatrend SR capsule 32mg and dilatrend tablet 25mg.

Conditions

• Essential Hypertension
• Chronic Stable Angina
• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Dilatrend SR capsule 32mg	* 1 capsule, oral, once daily, 7days * over the period I\&II(crossover)
DRUG	Dilatrend IR tablet 25mg	* 1 tablet, oral, once daily, 7days * over the period I\&II(crossover)

Timeline

• Start date: 2013-04-01
• Primary completion: 2013-05-01
• Completion: 2013-08-01
• First posted: 2013-03-28
• Last updated: 2013-04-01

Locations

1 site across 1 country: South Korea